Wasting as independent risk factor for mortality in chronic heart failure

The Lancet ◽  
1997 ◽  
Vol 349 (9058) ◽  
pp. 1050-1053 ◽  
Author(s):  
Stefan D Anker ◽  
Piotr Ponikowski ◽  
Susan Varney ◽  
Tuan Peng Chua ◽  
Andrew L Clark ◽  
...  
Keyword(s):  
Heart Failure ◽  
Risk Factor ◽  
Chronic Heart Failure ◽  
Independent Risk Factor

scholarly journals Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure

2005 ◽  
Vol 46 (6) ◽  
pp. 1019-1026 ◽  
Author(s):  
Wolfram Doehner ◽  
Mathias Rauchhaus ◽  
Piotr Ponikowski ◽  
Ian F. Godsland ◽  
Stephan von Haehling ◽  
...  
Keyword(s):  
Heart Failure ◽  
Risk Factor ◽  
Insulin Sensitivity ◽  
Chronic Heart Failure ◽  
Independent Risk Factor ◽  
Impaired Insulin

scholarly journals Reduction In body weight is an independent risk factor for mortality in chronic heart failure. Insights from GISSI-HF and Val-HeFT trials

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P1526-P1526
Author(s):  
P. Rossignol ◽  
S. Masson ◽  
S. Barlera ◽  
A. Castelnovo ◽  
C. Scardulla ◽  
...  
Keyword(s):  
Heart Failure ◽  
Body Weight ◽  
Risk Factor ◽  
Chronic Heart Failure ◽  
Independent Risk Factor

scholarly journals HIGH FUROSEMIDE DOSE IS AN INDEPENDENT RISK FACTOR FOR MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE

2012 ◽  
Vol 59 (13) ◽  
pp. E886
Author(s):  
John Terrovitis ◽  
Christos Kapelios ◽  
Elisavet Kaldara ◽  
George Sainis ◽  
Vassilios Sousonis ◽  
...  
Keyword(s):  
Heart Failure ◽  
Risk Factor ◽  
Chronic Heart Failure ◽  
Independent Risk Factor

Abdominal Obesity Is an Independent Risk Factor for Chronic Heart Failure in Older People

2006 ◽  
Vol 54 (3) ◽  
pp. 413-420 ◽  
Author(s):  
Barbara J. Nicklas ◽  
Matteo Cesari ◽  
Brenda W.J.H. Penninx ◽  
Stephen B. Kritchevsky ◽  
Jingzhong Ding ◽  
...  
Keyword(s):  
Heart Failure ◽  
Risk Factor ◽  
Chronic Heart Failure ◽  
Older People ◽  
Abdominal Obesity ◽  
Independent Risk Factor

scholarly journals The effect of renin-angiotensin system blockers on aldosterone levels in patients with chronic heart failure with preserved ejection fraction

2020 ◽  
Vol 11 (4) ◽  
pp. 67-73
Author(s):  
A. N. Shevelok
Keyword(s):  
Heart Failure ◽  
Risk Factor ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Ace Inhibitors ◽  
Independent Risk Factor ◽  
Preserved Ejection Fraction ◽  
Receptor Antagonists ◽  
Aldosterone Level

Objective: to evaluate the effect of renin-angiotensin-aldosterone system (RAAS) blockers on aldosterone level in patients with chronic heart failure with preserved ejection fraction (HFpEF).Materials and methods: the prospective study included 158 patients (58 men and 100 women, mean age 62,3 ± 7,4 years) with HFpEF (> 50 %) and left ventricular diastolic dysfunction. All patients had no history of primary aldosteronism and did not use the mineralocorticoid receptor antagonists during the last 6 weeks. We evaluated the duration of treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-2 receptor antagonists (ARA-2) and its average daily dose. The dose of RAAS blockers was assessed during previous 6 months as a percentage of target. Aldosterone plasma concentration was measured and the normal level was 40 – 160 pg/ml.Results: according to laboratory results 99 patients (62,7 %) had normal aldosterone level (nAld) and 59 patients (37,3 %) had high aldosterone level (hAld). hAld patients had significantly higher duration of RAAS blockers treatment (6 (3; 8) versus 4 (2; 5) years, p < 0,001) and dose (50 (25; 50) % vs 25 (12,5; 50) % of target, р=0,01). Multiple regression analysis showed that after standartization for age, severity of HFpEF, duration of arterial hypertension and comorbidity only long-term (more than 5 years) treatment with RAAS blockers remained the independent risk factor of high aldosterone level (odds ratio 3,16, 95 % confidence interval 2,08 – 8,24).Conclusions: in HFpEF patients’ plasma aldosterone level is closely associated with RAAS blockers treatment. Long-term (more than 5 years) therapy with ACE inhibitors or ARA-2 is the independent risk factor of secondary hyperaldosteronism. 

Abstract 4331: Elevated Albumin Excretion is an Independent Risk Factor in Patients with Chronic Heart Failure. Data from the GISSI-Heart Failure Trial

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Serge Masson ◽  
Luciano Moretti ◽  
Ospedale Mazzoni ◽  
Maria Grazia Rossi ◽  
Emanuele Carbonieri ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Risk Factor ◽  
Independent Risk Factor ◽  
Cox Model ◽  
Nyha Class ◽  
Large Population ◽  
Creatinine Concentration ◽  
Albumin Excretion ◽  
All Cause Mortality

Elevated albuminuria, a marker of endothelial renal damage, is a risk factor for cardiovascular events in the general population and in patients with diabetes or hypertension. We report here on its association with mortality in a large population of patients with chronic HF. Albuminuria (albumin/creatinine concentration ratio in a morning spot sample, UACR) was determined in 2131 patients with chronic HF enrolled in 77 centers participating to the GISSI-HF trial. Patients were divided according to normal (UACR <30 mg/g) and abnormal urinary excretion of albumin (≥30 mg/g). Association between elevated albuminuria and all-cause mortality was tested by univariable and multivariable analyses. Elevated albuminuria was found in 25.3% of the population (age 67±11 y, 78.9% males, 30.1% NYHA class III-IV, 55.5% hypertension, 26.1% diabetes) and was more frequent in older patients, those with reduced renal function, diabetes or high CRP. Mortality was significantly higher in patients with elevated albuminuria (20.1% at 1000 days) compared to normals (9.0%, p<0.0001). Elevated albuminuria remained an independent risk factor for all-cause mortality (HR [95%CI] 1.47 [1.18 –1.82]) in a Cox model adjusted for clinical risk factors such as age, gender, NYHA class, renal function, diabetes, BMI and blood pressure. About a quarter of the patients enrolled in the GISSI-HF trial had abnormal urinary albumin excretion, a marker for both renal and systemic vascular disease. We show for the first time in a large representative sample that elevated albuminuria is an independent predictor of all-cause mortality in patients with chronic HF.

scholarly journals Microalbuminuria as an independent risk factor for heart failure in the elderly patients with type 2 diabetes mellitus

2020 ◽  
Vol 49 (2) ◽  
Author(s):  
Enisa Karić ◽  
Zumreta Kušljugić ◽  
Enisa Ramić ◽  
Olivera Batić- Mujanović ◽  
Amila Bajraktarević ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Risk Factor ◽  
Diabetes Mellitus Type 2 ◽  
Independent Risk Factor ◽  
The Elderly ◽  
Diabetes Mellitus Type ◽  
Patients With Diabetes

Introduction:The study evaluated of microalbuminuria as a predictor of heart failure in patients with diabetes mellitus type 2.Materials and methods:The prospective study conducted in a period of time from 01-Feb-2007 to 01-Feb-2010.The study included 100 patients with type 2 diabetes, who had diabetes longer than 5 years. All subjects (average age 66 ± 10 years, 33% male, 67% female) were tested for the presence of microalbuminuria, and 50 patients had microalbuminuria. The second group comprised 50 patients without of microalbuminuria with diabetes mellitus type 2.Results:In the patients with microalbuminuria and diabetes mellitus were found 22% of heart failure and 6% in the second group. Average time to the occurance of heart failure in the first group was 32,5 months, in the second group was 35,3 months.Conclusions:The results show that microalbuminuria is an independent risk factor for heart failure in patients with diabetes mellitus type 2 and microalbuminuria. Patients without microalbuminuria had 3,7 less likely to development heart failure compared to patients with microalbuminuria and diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document